A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment

Phase 2

Completed

• Conditions: Overactive Bladder; Mild Cognitive Impairment
• Interventions: Drug: fesoterodine 4mg; Drug: Oxybutynin; Drug: placebo; Drug: fesoterodine 8mg

• Registration Number: NCT02240459
• Lead Sponsor: University of Alberta

Brief Summary

The purpose of this study is to assess the effects of fesoterodine at 4mg and 8mg doses versus a placebo and oxybutynin 5mg bid versus placebo on cognitive abilities in older people with overactive bladder and mild cognitive impairment.

Detailed Description

This is a randomized placebo controlled, blinded four way cross over trial of the effect of medications used to treat overactive bladder on the cognition of older men and women with mild cognitive impairment. Each treatment phase is a week, with a weeks washout period before starting the next treatment. Cognitive testing is by way of a validated computer assisted battery of tests

Study Timeline

• Study First Submitted: 2014-09-11
• Study First Submitted QC: 2014-09-12
• Study First Posted: 2014-09-15
• Study Start: 2016-08
• Primary Completion: 2020-01-31
• Study Completion: 2020-01-31
• Status Verified: 2020-02
• Last Update Submitted: 2020-02-18
• Last Update Posted: 2020-02-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 47

Inclusion Criteria

1. The subject is either male or female and ≥ 75 years of age.
2. The subject has OAB as determined by ICS criteria
3. The subject has mild cognitive impairment as determined by NIA criteria
4. The subject is competent to give informed consent and perform the tasks associated with the study
5. The subject has a body mass index (BMI) between 18.0 to 30.0 kg/m2 inclusive.
6. Written informed consent has been obtained.
7. The subject is available to complete the study.
8. At training visits (visit 2): the subject has performed at or above the minimum level on at least one occasion for each individual task measure in cognitive function test training.

Read More

Exclusion Criteria

1. The subject does not have OAB.
2. The subject has either dementia or moderate to severe cognitive impairment at screening.
3. The subject has probable clinical depression as determined by Geriatric Depression Scale (GDS) short form >5 at screening.
4. Subjects taking any cognitive enhancers (cholinesterase inhibitors or memantine).
5. The subject has a history of allergy to the study drug(s), to any component of the dosage form or any other allergy, which, in the opinion of the Investigator, contraindicates their participation.
6. The subject has any clinically significant abnormal heart rate or blood pressure measurements, at the screening visit, which, in the opinion of the Investigator, prevent safe participation in the study. (dBP< 60mmHg or > 90mmHg, sBP < 95mmHg or > 160mmHg or HR < 40bpm or > 100bpm).
7. Subjects with known history of urinary retention, severe gastrointestinal obstruction (including paralytic ileus or intestinal atony) or severe gastrointestinal conditions (including toxic megacolon or ulcerative colitis), myasthenia gravis, uncontrolled narrow angle glaucoma or shallow interior chamber or subjects deemed to be at risk for these conditions.
8. Subjects undergoing haemodialysis or who have severe renal impairment.
9. Subjects with severe hepatic impairment, defined as Child-Pugh grade IV.
10. Subjects taking potent CYP 3A4 inhibitors which would, under normal circumstances, require adjustment of the dose of the test drugs.
11. Subject has taken prescribed medication within 14 days prior to the first study day or over-the-counter medicine (including vitamins and herbal remedies) within 48 hours prior to the first study day, which in the opinion of the Investigator, will interfere with the study procedures or compromise safety.
12. Subject has an average weekly alcohol intake of greater than 21 units (male) or 14 units (female) within the 90 days prior to the study. 1 unit is 270cc of beer, 40cc of spirits or 125cc of wine.
13. History of smoking more than 10 cigarettes (or the equivalent amount of tobacco) per day within the 90 days prior to the study.
14. Subject has participated in any clinical study within the last 90 days.
15. Any clinically significant abnormality following Investigator review of the pre study physical examination.
16. Any clinical condition, which, in the opinion of the Investigator, would not allow safe completion of the study.
17. Any subjects who, in the opinion of the investigator, may find it difficult to adhere to the provisions of treatment and observation specified in the protocol.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Fesoterodine 4mg daily	fesoterodine 4mg	fesoterodine 4mg oral
Fesoterodine 4mg daily	placebo	fesoterodine 4mg oral
Fesoterodine 4mg daily	fesoterodine 8mg	fesoterodine 4mg oral
Fesoterodine 8mg	fesoterodine 4mg	Fesoterodine 8mg in form of 2, 4mg tablets
Fesoterodine 8mg	Oxybutynin	Fesoterodine 8mg in form of 2, 4mg tablets
Fesoterodine 8mg	placebo	Fesoterodine 8mg in form of 2, 4mg tablets
Fesoterodine 8mg	fesoterodine 8mg	Fesoterodine 8mg in form of 2, 4mg tablets
oxybutynin	fesoterodine 4mg	oxybutynin immediate release, encapsulated 2, 5mg capsules daily
oxybutynin	fesoterodine 8mg	oxybutynin immediate release, encapsulated 2, 5mg capsules daily
placebo capsule	fesoterodine 4mg	placebo capsule, 2 per day
placebo capsule	placebo	placebo capsule, 2 per day
placebo capsule	fesoterodine 8mg	placebo capsule, 2 per day
oxybutynin	placebo	oxybutynin immediate release, encapsulated 2, 5mg capsules daily
Fesoterodine 4mg daily	Oxybutynin	fesoterodine 4mg oral
oxybutynin	Oxybutynin	oxybutynin immediate release, encapsulated 2, 5mg capsules daily
placebo capsule	Oxybutynin	placebo capsule, 2 per day

Primary Outcome Measures

Name	Time	Method
continuity of attention	1 and 4h post dose	Continuity of Attention: Accuracy of responding in Choice Reaction Time task Percent Target Detection in Digit Vigilance task False Alarms in Digit Vigilance task

Secondary Outcome Measures

Name	Time	Method
cognitive function	1 and 4h post last dose of study drug	includes the following domains of cognition; * power of attention,; * quality of working memory,; * quality of episodic secondary memory,; * speed of memory; * Montreal Cognitive assessment score

Trial Locations

Locations (1)

Division of Geriatric Medicine, Clinical Sciences Building, University of Alberta Hosp; 🇨🇦 Edmonton, Alberta, Canada